Method of treating lower urinary tract disorders
First Claim
1. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject a therapeutically effective amount of a compound of Formula I:
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.
-
Citations
70 Claims
- 1. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject a therapeutically effective amount of a compound of Formula I:
- 36. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject a therapeutically effective amount of a compound represented by Formula II:
- 41. A method of treating at least one symptom of overactive bladder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject a therapeutically effective amount of a compound represented by Formula II:
- 43. A method of treating at least one symptom of interstitial cystitis in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject a therapeutically effective amount of a compound represented by Formula II:
-
45. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject:
-
a) a first amount of a 5-HT3 receptor antagonist; and
b) a second amount of a noradrenaline reuptake inhibitor wherein the first and second amounts together comprise a therapeutically effective amount. - View Dependent Claims (46, 47, 48, 49, 50, 51, 52, 53)
-
-
54. A method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment, wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, nocturia and enuresis, comprising administering to said subject:
-
a) a therapeutically effective amount of a 5-HT3 receptor antagonist; and
b) a therapeutically effective amount of a noradrenaline reuptake inhibitor. - View Dependent Claims (55, 56, 57, 58, 59, 60, 61, 62)
-
-
63. A method for processing a claim under a health insurance policy submitted by a claimant seeking reimbursement for costs associated with treatment of at least one symptom of a lower urinary tract disorder wherein, said treatment comprises coadministering to a subject a first amount of a 5-HT3 receptor antagonist and a second amount of a noradrenaline reuptake inhibitor, wherein the first and second amounts together comprise a therapeutically effective amount comprising:
-
a) reviewing said claim;
b) determining whether said treatment is reimbursable under said insurance policy; and
c) processing said claim to provide partial or complete reimbursement of said costs. - View Dependent Claims (64, 65, 66)
-
-
67. A method for processing a claim under a health insurance policy submitted by a claimant seeking reimbursement for costs associated with treatment of at least one symptom of a lower urinary tract disorder wherein, said treatment comprises coadministering to a subject a therapeutically effective amount of a 5-HT3 receptor antagonist and a therapeutically effective amount of a noradrenaline reuptake inhibitor comprising:
-
a) reviewing said claim;
b) determining whether said treatment is reimbursable under said insurance policy; and
c) processing said claim to provide partial or complete reimbursement of said costs. - View Dependent Claims (68, 69, 70)
-
Specification